CRISPR Therapeutics Reports Q1 2026 Results; All Eyes on Casgevy Infusion Cadence and Cash Burn

What happened

CRISPR Therapeutics reported its first quarter 2026 financial results on May 4, providing the first look at the Casgevy launch trajectory in the new year. Consistent with the prior year's dynamics, collaboration expense likely continued to weigh on reported losses as the company loses the deferral benefit that masked costs in 2024. The key operational metrics to watch are Casgevy infusions and first cell collections, which will indicate whether the funnel from patient initiations to actual treatments is converting as hoped. Additionally, any disclosure on ATM drawdowns during the quarter will signal management's discipline on dilution. Given the master report's assessment that the stock is priced for a loss-narrowing narrative, the Q1 print must show sequential improvement in net loss and stable cash consumption to support the current valuation.

Implication

Investors should focus on the reported infusion numbers and collaboration expense details, as these are the leading indicators of whether the bear or base case is unfolding. If infusions fail to accelerate from the 4Q25 pace of 30, the stock may drift toward the $45 downside scenario as operational bottlenecks persist. Conversely, if infusions meaningfully exceed 40 and ATM usage remains negligible, the bull case with $80 upside becomes more plausible. However, the master report cautions that management's own guidance suggests losses will remain elevated, so any near-term beat may be temporary. The prudent approach is to await confirmation over two to three quarters before committing capital.

Thesis delta

The Q1 2026 release provides the first real test of whether the 2025 funnel (147 collections, 64 infusions) is converting into a higher infusion run rate and whether collaboration expense growth is stabilizing. If the data shows meaningful throughput improvement without increased ATM draws, the thesis shifts from 'wait for proof' to 'early confirmation of execution.' However, if numbers mirror 4Q25 or show regression, the thesis weakens, and the stock may trend toward the bear case.